Douglas A. Nelson, MD
Whether its immunotherapy in colorectal cancer (CRC) or chemotherapy in pancreatic cancer, a common thread among these gastrointestinal (GI) malignancies has been the investigation of these agents in earlier settings, explained Douglas A. Nelson, MD.
“I believe immunotherapy has a role in earlier lines of CRC,” he said. “In other diseases, immunotherapy started out in advanced third-line refractory settings and moved into the frontline setting, often in combination with chemotherapy. I hope that's where we're heading in CRC. There's a lot of promise in that.”
With regard to immunotherapy, data from the 2018 ESMO Congress showed a major pathologic response in 100% of patients (n = 7) with early-stage mismatch repair–deficient (dMMR) colon cancer who were treated with the combination of neoadjuvant nivolumab (Opdivo) and ipilimumab (Yervoy). Moreover, 4 patients achieved a complete response.
... to read the full story